{"schema_version":"secwatch.filing_event.v1","accession":"0000879169-22-000007","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.826677+00:00","generated_at":"2026-06-22T20:40:50.525190+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M","bullets":["Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).","GAAP diluted EPS $0.50 (vs $0.82 YoY); Non-GAAP diluted EPS $0.60 (vs $1.18).","Jakafi FY22 guidance low end raised to $2.38-2.40B; other Hem/Onc rev guidance lowered to $200-210M on FX.","Pending acquisition of Villaris (auremolimab anti-IL-15Rβ mAb) for vitiligo; clinical start 2023.","Pipeline: once-daily ruxolitinib XR PDUFA Mar 23, 2023; axatilimab cGVHD results mid-2023; povorcitinib Ph3 HS end-2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000879169-22-000007","json":"https://secwatch.observer/filing/0000879169-22-000007.json","markdown":"https://secwatch.observer/filing/0000879169-22-000007.md","text":"https://secwatch.observer/filing/0000879169-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/0000879169-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/incy-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:40:50.525190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7357ecdfe31a6ece54c43518537bfd489dbc06a","claim":"INCYTE CORP reported third fiscal quarter ended September 30, 2022 results: revenue $713 million. Guidance raised.","evidence_excerpt":"Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura TM (ruxolitinib) cream net product revenues – Jakafi net product rev enues of $620 million in Q3’22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/0000879169-22-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third fiscal quarter ended September 30, 2022"},{"label":"Revenue","value":"$713 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}